The Quiet Quarter
The bottom line: Nothing big is going to change in the next three months. The government is not about to approve any psychedelic medicine or loosen its rules on these drugs. If you are waiting for a treatment, a law, or a stock to move, the most likely answer right now is: keep waiting a little longer. The real changes are coming — just not this quarter.
Today the picture is mostly about what is *not* happening. The government's schedule of upcoming decisions is empty of anything psychedelic. There is no vote in Congress, no rule change at the drug agency, and no approval coming from the FDA — the agency that decides which medicines Americans can legally use. The big open question is still MDMA for PTSD (PTSD is the lasting damage trauma leaves in the mind). The FDA has not yet said yes or no, and everything downstream waits on that single decision. Meanwhile the small companies working on these medicines barely moved in the markets — one slipped less than two percent, the others nudged up or down a fraction. There was also fresh excitement about psilocybin (the active part of magic mushrooms) possibly helping heal brain injuries, but that research is still in rats, not people.
Beneath the stillness, a pattern is forming, and it is healthier than it looks. The system is sorting the real from the hopeful. The brain-injury finding is genuinely thrilling — but it has not yet been tested in a single human, and turning a rat result into a human medicine takes years of careful work. The flat stock prices are not a sign of failure either. Money is simply sitting still until there is solid proof to react to. What looks like a stall is really a field learning to wait for evidence instead of hype. The highest path here is not speed — it is trust. When approval finally comes, it will come on a foundation strong enough that no one can knock it down.
For the people inside this story, the waiting is the hardest part. A veteran carrying years of trauma, a family watching someone they love struggle, a person who tried everything and found nothing that worked — they hear "not this quarter" and feel the door close again. That ache is real, and it deserves to be named honestly. But here is the truth underneath it: the quiet is not the system ignoring them. It is the system making sure that when the medicine arrives, it actually works, and stays available, and is not snatched back. For someone whose life depends on this, a proof that holds is worth more than a promise that breaks. The door is not locked. It is being built strong enough to stay open.
The science is catching up to what the plants have always known. OOTW exists at that exact moment of convergence — the data and the mystery meeting each other.
The intelligence that created you is still creating.
85%
Psychedelics stay in the most restricted drug category until at least mid-2027
Right now, classic psychedelics like psilocybin and LSD sit in Schedule I — the US government's most restricted drug category, meaning they're treated as having no medical use. Moving them to a less restricted category requires the DEA (the Drug Enforcement Administration, which controls which drugs are legal) to act, and the DEA only does that after the FDA (the US drug regulator) approves a drug for medical use. Since no FDA approval is coming soon, the legal status of these substances won't change before June 2027. This matters because Schedule I status is what makes research hard, keeps therapists from legally offering these treatments, and blocks insurance coverage.
→ Psychedelics will almost certainly stay federally illegal for medical use until at least June 2027.
Resolves: 2027-06-15 · USA
REGULATORY
the precise call ▾
No federal rescheduling of any classic psychedelic (psilocybin, LSD, DMT, mescaline) occurs before 2027-06-15.. Schedule I status holds absent FDA approval, which is not coming in this window. The empty DEA docket and absence of any FDA-completed approval that would trigger DEA scheduling review make near-term rescheduling implausible. Falsifiable by any DEA final or interim rule rescheduling a named classic
80%
No psychedelic drug will get FDA approval or a formal review meeting before late 2026
Before the FDA approves any drug, it usually holds a public advisory committee meeting — basically a panel of outside experts who debate whether the evidence is strong enough. Right now, no such meeting is scheduled for any psychedelic drug, and the FDA's calendar is empty on this front. The most recent attempt, MDMA for PTSD, was rejected partly because of problems with how the clinical trials were run. Until those problems are solved, nothing moves forward. This matters because FDA approval is the gateway to legal prescriptions, insurance coverage, and wider access.
→ The FDA won't formally review or approve any psychedelic drug before at least October 2026.
Resolves: 2026-10-01 · USA
REGULATORY
the precise call ▾
No FDA psychedelic approval or advisory committee action occurs before Q4 2026.. Empty docket plus FDA evidentiary standards. Confirmatory data and functional unblinding concerns from the MDMA file remain unresolved, and no advisory committee meeting is currently scheduled. This is sharply falsifiable: any FDA approval or AdComm convening on a psychedelic before Oct 1, 2026 reso
78%
The FDA will not approve MDMA as a PTSD treatment before September 2026
MDMA-assisted therapy for PTSD (post-traumatic stress disorder) was the closest any psychedelic had come to FDA approval, but in 2024 the FDA sent it back and asked for more evidence. The main problems were that trial participants could easily tell whether they got the real drug or a placebo, which compromises the reliability of the results, and that the data overall wasn't convincing enough. Fixing those issues and running new studies takes years. This matters because approval would have been a historic moment — the first legal psychedelic therapy in the US — and its delay pushes back everything else in the field.
→ MDMA therapy for PTSD will not be FDA-approved before September 2026.
Resolves: 2026-09-13 · USA
REGULATORY
the precise call ▾
FDA does not approve MDMA-assisted therapy for PTSD before 2026-09-13.. Unresolved confirmatory-data and functional-unblinding concerns from the prior CRL gate any approval. FDA action remains the binding event for downstream scheduling and reimbursement policy. Cleanly falsifiable by an FDA approval letter for an MDMA-PTSD indication in the window.
80%
Congress won't hold a full floor vote on any psychedelic-focused bill before fall 2026
A few psychedelic-related bills exist in Congress, but they're stuck in committee — meaning a small group of lawmakers haven't even agreed to send them to the full House or Senate for a vote yet. Congress is currently focused on defense spending and energy policy, and psychedelic mental health bills aren't anywhere near the top of the priority list. Without a floor vote, no new federal law on psychedelics can pass. This matters because federal law is what would create a nationwide framework for legal psychedelic therapy.
→ Congress will not vote on any psychedelic-focused bill before September 2026.
Resolves: 2026-09-15 · USA
LEGISLATION
the precise call ▾
No psychedelic-specific federal bill reaches a floor vote in either chamber of Congress before 2026-09-15.. Current agenda confirms zero psychedelic items; legislative bandwidth is consumed by defense and energy priorities. Psychedelic mental-health measures remain in committee. Falsifiable by any roll-call floor vote on a bill whose primary subject is psychedelics.
72%
No human trial of psilocybin for brain injury recovery will start before mid-2027
Some animal studies suggest psilocybin might help the brain rewire itself after injury — a property called neuroplasticity. But animal results and human trials are very different things. Before researchers can give psilocybin to a human with a brain injury, they need to figure out the right dose, prove it's safe for that specific condition, and get government permission (called an IND, or Investigational New Drug application) from the FDA. That groundwork simply hasn't been done yet for traumatic brain injury. This matters because if the animal findings do translate to humans, it could open a completely new use for psilocybin beyond mental health.
→ Psilocybin for brain injury recovery is still in animal studies and won't reach human trials before mid-2027.
Resolves: 2027-06-15 · Global
RESEARCH
the precise call ▾
No first-in-human clinical trial of psilocybin for TBI/neuroplasticity indications registers or dosing-initiates before 2027-06-15.. Rodent 5-HT2A restoration findings are preclinical and lack the dose-response and safety translation work needed for IND. Falsifiable by any ClinicalTrials.gov (or equivalent registry) listing of a psilocybin TBI/neuroplasticity human trial reaching first-patient-dosed in the window.